Want to see LRMR full AI Analyst Report?
Top Page
Larimar Therapeutics
(NASDAQ:LRMR)
Select Model
Select Model
Rating:47Neutral
Price Target:
$3.00
▼(-28.06% Downside)
Action:Reiterated
Date:09/30/26
The score is held down primarily by weak financial performance (no revenue, widening losses, and heavy cash burn) and bearish technicals (below key moving averages with negative MACD). Offsetting factors are positive corporate developments (regulatory/clinical progress and strengthened leadership) and a valuation component that is difficult to assess due to negative earnings and no stated dividend yield.
Positive Factors
Regulatory pathway progress for nomlabofusp
FDA alignment on a surrogate endpoint and rolling BLA provides a clearer regulatory path for nomlabofusp than a conventional development route. If execution remains on schedule, this could shorten the path toward potential approval and materially improve the company’s strategic and commercial prospects.
Negative Factors
No revenue and widening losses
Larimar has no established product revenue to offset its research and development costs, leaving financial performance dependent on future clinical and regulatory success. Widening losses indicate a rising expense base and increase the company’s exposure to additional financing, dilution, and execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory pathway progress for nomlabofusp
FDA alignment on a surrogate endpoint and rolling BLA provides a clearer regulatory path for nomlabofusp than a conventional development route. If execution remains on schedule, this could shorten the path toward potential approval and materially improve the company’s strategic and commercial prospects.
Read all positive factors
Larimar Therapeutics (LRMR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$326.19M
Dividend YieldN/A
Average Volume (3M)1.19M
Price to Earnings (P/E)―
Beta (1Y)1.86
Revenue GrowthN/A
EPS Growth-27.00%
CountryUS
Employees71
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.99
Shares Outstanding103,882,935
10 Day Avg. Volume1,800,503
30 Day Avg. Volume1,186,880
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.56
Price to Sales (P/S)0.00
P/FCF Ratio-2.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.75Price Target Upside253.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.39
Revenue Forecast (FY)N/A
Larimar Therapeutics Business Overview & Revenue Model
Company Description
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology pl...
How the Company Makes Money
As a clinical-stage biotechnology company without approved commercial products, Larimar Therapeutics primarily generates revenue, when applicable, from collaboration and license arrangements (e.g., upfront payments, milestone payments tied to deve...
Larimar Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -172.30M | -165.32M | -80.29M | -36.64M | -35.04M | -50.31M |
| Net Income | -172.60M | -165.67M | -80.60M | -36.95M | -35.35M | -50.64M |
Balance Sheet | ||||||
| Total Assets | 165.30M | 145.84M | 200.22M | 95.94M | 126.41M | 78.67M |
| Cash, Cash Equivalents and Short-Term Investments | 156.27M | 136.85M | 183.45M | 86.79M | 118.43M | 70.10M |
| Total Debt | 4.96M | 4.07M | 5.12M | 5.55M | 5.41M | 6.00M |
| Total Liabilities | 37.92M | 67.76M | 28.41M | 14.21M | 15.50M | 14.25M |
| Stockholders Equity | 127.38M | 78.08M | 171.81M | 81.72M | 110.90M | 64.41M |
Cash Flow | ||||||
| Free Cash Flow | -156.08M | -113.29M | -71.28M | -33.62M | -27.67M | -42.44M |
| Operating Cash Flow | -155.92M | -113.20M | -70.76M | -33.46M | -27.57M | -42.10M |
| Investing Cash Flow | 55.11M | 100.31M | -85.39M | 33.35M | -90.96M | 24.17M |
| Financing Cash Flow | 172.77M | 65.09M | 161.88M | 30.00K | 75.26M | 19.89M |
Larimar Therapeutics Technical Analysis
Negative
4.17
Price Trends
3.92
Negative
3.74
Negative
3.94
Negative
Market Momentum
-0.20
Positive
33.33
Neutral
14.53
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LRMR, the sentiment is Negative. The current price of 4.17 is above the 20-day moving average (MA) of 3.69, above the 50-day MA of 3.92, and above the 200-day MA of 3.94, indicating a bearish trend. The MACD of -0.20 indicates Positive momentum. The RSI at 33.33 is Neutral, neither overbought nor oversold. The STOCH value of 14.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LRMR.
Larimar Therapeutics Risk Analysis
Larimar Therapeutics disclosed 85 risk factors in its most recent earnings report. Larimar Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
We initiated our rolling BLA submission to the FDA for marketing approval of nomlabofusp using the accelerated approval pathway and expect to submit the remaining modules in the second half of 2026; however, there can be no assurance that we will submit the remaining modules on our expected timeline, that the FDA will accept the BLA for filing or the FDA will approve our BLA submission for accelerated approval. Q2, 2026
Larimar Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $1.39B | 9.97 | -109.40% | ― | ― | ― | |
55 Neutral | $304.13M | -1.06 | -84.95% | ― | 6.02% | -305.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $832.52M | -7.40 | -89.38% | ― | ― | -108.75% | |
47 Neutral | $326.19M | -1.61 | -137.39% | ― | ― | -27.00% | |
43 Neutral | $209.04M | -3.61 | 72.64% | ― | 51.98% | 17.68% | |
43 Neutral | $127.32M | -0.48 | -242.28% | ― | ― | 21.31% |
* Healthcare Sector Average
LRMR
Larimar Therapeutics
3.20
-0.96
-23.01%
OMER
Omeros
19.04
14.90
359.90%
VNDA
Vanda
4.91
-0.19
-3.73%
FHTX
Foghorn Therapeutics
3.57
-1.36
-27.59%
CADL
Candel Therapeutics
10.44
4.90
88.45%
NMRA
Neumora Therapeutics, Inc.
0.60
-1.18
-66.52%
Larimar Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Larimar Therapeutics Appoints New President and COO
Positive
Sep 29, 2026
On September 29, 2026, Larimar Therapeutics appointed John B. Harlow Jr. as president and chief operating officer under an employment agreement that includes a $560,000 base salary, performance-based bonus eligibility, and standard executive sever...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Larimar reports Q2 results and nomlabofusp progress
Positive
Aug 4, 2026
On August 4, 2026, Larimar Therapeutics reported its second-quarter 2026 financial and business results, highlighting progress in the development of its lead Friedreich’s ataxia candidate nomlabofusp. Longer-term open-label study data releas...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.